Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

2.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
2.9K
Repressible Operon: trp Operon01:21

Repressible Operon: trp Operon

908
The trp operon in Escherichia coli exemplifies a repressible operon. It regulates the synthesis of tryptophan through repressor-mediated transcriptional control and attenuation. This dual regulatory mechanism ensures tryptophan biosynthesis occurs only when needed, conserving cellular resources.Structure of the trp OperonThe trp operon consists of five structural genes (trpE, trpD, trpC, trpB, and trpA) that encode enzymes for tryptophan biosynthesis. These genes are transcribed as a single...
908
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

4.3K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.3K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

836
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
836
Transcription Attenuation in Prokaryotes02:42

Transcription Attenuation in Prokaryotes

17.7K
Transcriptional attenuation occurs when RNA transcription is prematurely terminated due to the formation of a terminator mRNA hairpin structure.  Bacteria use these hairpins to regulate the transcription process and control the synthesis of several amino acids including histidine, lysine, threonine, and phenylalanine. Transcription attenuation takes place in the non-coding regions of mRNA.
There are several different mechanisms used to attenuate transcription. In ribosome mediated...
17.7K
T Cell Types and Functions01:24

T Cell Types and Functions

1.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Atomic resolution cryo-EM at 200 keV.

IUCrJ·2026
Same author

CCDC32 collaborates with the membrane to assemble the AP-2 clathrin adaptor complex.

Science advances·2026
Same author

Usefulness of pegfilgrastim for allogeneic peripheral blood stem cell collection from healthy donors.

Transfusion·2026
Same author

Effect of PEG Chain Length on the Water Solubility of Monodisperse PEG-Appended Molecules.

The journal of physical chemistry. B·2026
Same author

Epidemiology and clinical characteristics of hospitalized patients with echinococcosis in Japan: A nationwide administrative database study.

Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy·2026
Same author

intDesc-AbMut: A Tool for Describing and Understanding How Antibody Mutations Impact Their Environmental Interactions.

Computational and structural biotechnology journal·2026
Same journal

PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction.

Nature communications·2026
Same journal

PfApiAT2 is a proline transporter essential for the transmission of Plasmodium falciparum by the mosquito vector.

Nature communications·2026
Same journal

Transient distortions of the South Atlantic Anomaly radiation environments driven by electric fields.

Nature communications·2026
Same journal

Structural basis of the regulation by CDK11 kinase of early spliceosome activation and evidence for its proofreading by DHX15 helicase.

Nature communications·2026
Same journal

Structural and mechanistic insights into primer synthesis initiation by DNA primase.

Nature communications·2026
Same journal

Changes in heritability and shared environmentality of educational attainment across twentieth-century Norway.

Nature communications·2026
See all related articles

Related Experiment Video

Updated: Dec 5, 2025

Author Spotlight: AQRNA-seq Role in Mapping Small RNAs and Unraveling Protein Translation Mechanisms
05:12

Author Spotlight: AQRNA-seq Role in Mapping Small RNAs and Unraveling Protein Translation Mechanisms

Published on: February 2, 2024

1.1K

Structural analysis reveals TLR7 dynamics underlying antagonism.

Shingo Tojo1, Zhikuan Zhang2, Hiroyuki Matsui3

  • 1Sumitomo Dainippon Pharma Co., Ltd., 3-1-98 Kasugade-naka, Konohana-ku, Osaka, 554-0022, Japan. shingo-tojo@ds-pharma.co.jp.

Nature Communications
|October 16, 2020
PubMed
Summary
This summary is machine-generated.

Researchers developed novel Toll-like receptor 7 (TLR7) antagonists to treat autoimmune diseases like lupus. These small molecules protect against lethal autoimmunity by targeting the TLR7 receptor

More Related Videos

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.8K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.1K

Related Experiment Videos

Last Updated: Dec 5, 2025

Author Spotlight: AQRNA-seq Role in Mapping Small RNAs and Unraveling Protein Translation Mechanisms
05:12

Author Spotlight: AQRNA-seq Role in Mapping Small RNAs and Unraveling Protein Translation Mechanisms

Published on: February 2, 2024

1.1K
Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
09:51

Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

Published on: July 26, 2017

12.8K
Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation
12:09

Use of Single Chain MHC Technology to Investigate Co-agonism in Human CD8+ T Cell Activation

Published on: February 28, 2019

10.1K

Area of Science:

  • Immunology
  • Structural Biology
  • Drug Discovery

Background:

  • Toll-like receptor 7 (TLR7) plays a role in immune responses by recognizing RNA and nucleosides.
  • Aberrant TLR7 activation is linked to autoimmune diseases, particularly systemic lupus erythematosus (SLE).

Purpose of the Study:

  • To develop specific TLR7 antagonists for treating SLE.
  • To elucidate the structural mechanisms underlying TLR7 antagonism.

Main Methods:

  • Modification of known TLR7 agonists to create antagonists.
  • In vivo studies in mice to assess therapeutic efficacy against autoimmunity.
  • Crystallography and cryo-electron microscopy to determine receptor structure.

Main Results:

  • Developed potent and specific small-molecule TLR7 antagonists.
  • Demonstrated protection of mice against lethal autoimmune responses.
  • Identified the open receptor conformation and the structural equilibrium between open and closed states.
  • Revealed the detailed binding mechanism of antagonists within the TLR7 pocket.

Conclusions:

  • Small-molecule TLR7 antagonists are promising therapeutic agents for SLE.
  • Targeting TLR7 offers a viable strategy for treating autoimmune diseases.
  • Structural insights provide a basis for further drug development.